Clinical Milestones at ESMO Congresses Reshaping Cancer Care
A congress presentation lasts minutes, but its consequences can reshape years of patient care. The European Society for Medical Oncology (ESMO) annual congresses serve as a global stage for practice-changing clinical trials across various cancer types. Over the past decade, key studies presented at these gatherings have altered real-world treatment decisions, shifting which therapies doctors start first, how they manage post-treatment intervals, and how they reduce the risk of cancer recurrence.
MONALEESA-2 Trial Results at ESMO 2016
Endocrine therapy controlled hormone receptor-positive, HER2-negative advanced breast cancer, but tumors frequently developed resistance. To test whether adding an oral drug could extend disease control, investigators launched the MONALEESA-2 trial. Gabriel Hortobagyi, who chaired the trial, noted at the ESMO 2016 press briefing that the research built on decades of work. Ribociclib emerged from a collaboration between the Novartis Institutes for BioMedical Research and Astex announced in December 2005. The oral drug selectively inhibits CDK4 and CDK6 proteins, interrupting cell-cycle machinery while letrozole reduced hormonal growth signals.
The trial enrolled 668 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who received no prior systemic treatment for advanced disease. At ESMO 2016, initial results showed that adding ribociclib reduced the hazard of progression or death by approximately 44%. Five years later at ESMO 2021, Hortobagyi presented overall-survival results showing a median survival of 63.9 months with ribociclib plus letrozole compared with 51.4 months with letrozole alone. Today, this combination stands as a standard first-line approach for metastatic HR-positive, HER2-negative breast cancer, requiring routine monitoring of blood counts, liver function, and electrocardiograms.
KEYNOTE-024 Trial Results in Copenhagen
For patients with metastatic non-small cell lung cancer lacking actionable driver alterations, platinum-based chemotherapy long served as the default starting point. The KEYNOTE-024 trial tested whether pembrolizumab, an antibody blocking PD-1, could replace chemotherapy as a first-line monotherapy. Martin Reck presented findings at ESMO 2016 showing that pembrolizumab alone could replace platinum-based chemotherapy as first-line treatment.
The five-year analysis presented at ESMO 2020 demonstrated a median overall survival of 26.3 months with pembrolizumab compared with 13.4 months with chemotherapy. Reck discussed in VJOncology’s The Lung Cancer Sessions: ESMO 2020 that many earlier trials ended follow-up too early, while KEYNOTE-024 extended the observation horizon. Pembrolizumab alone remains a standard first-line option for selected patients with high PD-L1 expression.
PACIFIC Trial Findings Presented in Madrid
For patients with unresectable stage III non-small cell lung cancer, completing concurrent platinum-based chemotherapy and radiation was historically followed by surveillance and uncertainty. The PACIFIC trial asked whether adding consolidation immunotherapy could extend disease control. Luis Paz-Ares presented findings at the ESMO 2017 press conference, explaining that no major advances had occurred in that setting over the preceding two decades.
The trial randomized patients whose disease had not progressed after chemoradiotherapy to receive durvalumab or placebo. Initial readouts showed a median progression-free survival of 16.8 months with durvalumab versus 5.6 months with placebo.